Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SUBOXONE® sublingual film
SUBOXONE film · 1 trial · 2 indications
TEAE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= a marked limitation in activity. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent one of the outcomes listed in this definition.
Vital signs include * systolic blood pressure (mmHg) * diastolic blood pressure (mmHg) * respiratory rate (breaths/minute) * weight (kg) * body mass index (kg/m\^2) * waist-to-hip ratio Baseline is defined as the last non-missing value prior to subcutaneous injection of RBP-6000 on Day 1.
The C-SSRS asks questions of study participants regarding whether they had suicidal ideation and/or suicidal behavior since the last visit using the electronic version of the scale. Only the most severe assessment is reported in this summary. Participants who experienced suicidal ideation and suicidal behavior are only summarized in the suicidal behavior since behavior is more severe than ideation. C-SSRS baseline version was completed during the screening visit. C-SSRS 'since-last-visit' version was completed weekly for the first month and at least every month until the end of the study. Shift table category titles are structured as: baseline category/treatment category. The category 'No Suicidal Ideation or Behaviour' has been abbreviated as 'No Suicidal I or B'.
Injection site pain as measured by participant-reported VAS. The participant-reported VAS for injection site pain was measured on a 100 mm scale with 'no pain' at 0 mm and 'strongest pain ever' at 100 mm (total scale of 0-100). Participants marked where along the scale reflected their localized injection pain. The injection site pain VAS scores were obtained (after the completion of the injection) within 1 minute and at 5, 10, 15, 30 and 60 minutes (+- 5 minutes). The timing of the injection site pain VAS should have been measured from the end of the injection. Data represents the worst pain recorded for each participant across all injections and all VAS records. The mean value is presented. De Novo subjects were given injections on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281 and 309. Roll-over subjects were given injections on Days 1, 29, 57, 85, 113, 141.
| Arm | Type | Description |
|---|---|---|
| Roll-over Subjects | EXPERIMENTAL | Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period. |
| De Novo Subjects | EXPERIMENTAL | Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period. |
| Name | Type | Description |
|---|---|---|
| SUBOXONE sublingual film | DRUG | SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period. |
| RBP-6000 | DRUG | Injections administered subcutaneously every 28 days on alternate sides of participant's abdomen starting at 300 mg. Subsequent doses of RBP-6000 could be adjusted down to 100 mg with the possibility of adjusting back up to 300 mg based on the medical judgment of the investigator. De novo subjects receive up to 12 injections and roll-over subjects receive up to 6 injections. |
Inclusion Criteria: De novo subjects: * Seeking treatment for opioid use disorder (OUD) and for the previous 3 months meet the Diagnostic and Statistical Manual 5 (DSM-5) criteria for moderate or severe OUD * Appropriate candidate for opioid partial-agonist treatment * BMI between 18 and 35, inclu...
SUBOXONE film is a sublingual film being studied for the treatment of opioid use disorder. It is a small-molecule therapy in the psychiatry therapeutic area. The clinical program has focused on treatment-seeking subjects with opioid use disorder and opioid-related disorders.
SUBOXONE film is developed by Supernus Pharmaceuticals, Inc., which trades under the ticker SUPN. The company is the sponsor associated with the Phase 3 clinical program for the sublingual film in opioid use disorder.
SUBOXONE film is in Phase 3 clinical development for opioid use disorder. It is investigational, and the Phase 3 trial in the program has been completed. The program includes one completed trial with total enrollment of 775 participants.
SUBOXONE film has been studied in the Phase 3 trial NCT02510014, titled Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder. The trial was completed, enrolled 775 participants, used a controlled design, and was conducted in the United States with participants aged 18 years and older.
Yes, SUBOXONE film is the same product as SUBOXONE sublingual film. Other names used for it include SUBOXONE® sublingual film and SUBOXONE Sublingual Film. These names refer to the same sublingual film formulation being developed by Supernus Pharmaceuticals for opioid use disorder.
SUBOXONE film is a small-molecule drug formulated as a sublingual film. It is being developed in the psychiatry therapeutic area for opioid use disorder. The Phase 3 program enrolled 775 participants in a controlled trial conducted in the United States.